Boehringer takes Imdelltra rival straight to first line
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
Cell therapies head for the clinic
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Gilead puts its Car-T money where its mouth is
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
Pan-KRAS gets even more crowded
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
AACR 2026 – private biotechs score plenaries
Circle Pharma and Verismo feature in coveted sessions.
Like Lilly, Novartis bets against mutation specificity
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
AACR 2026 – one more shot for integrins
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
AACR 2026 – conjugates remain centre stage
Single, double and even triple-payload ADCs will be presented at the meeting.
